# US 2019/0314308 A1 · Treatment of fragile x syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314308 A1
- Document ID: US20190314308A1
- Status: Published application
- Kind: A1
- Application number: 16/383,028
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Healx Limited
- Applicants: Healx Limited
- Inventors: David Brown
- Web page: https://patentgrep.com/patent/US20190314308A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of treating fragile x syndrome comprising administering to a subject in need thereof a therapeutically effective amount of sulindac or a pharmaceutically acceptable salt thereof.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject is human.

### Claim 17 (depends on 14)

The method of claim 14, wherein a dose of 50 mg to 400 mg of sulindac is administered.

### Claim 18 (depends on 14)

The method of claim 14, wherein a dose of 50 mg to 300 mg of sulindac is administered.

### Claim 19 (depends on 14)

The method of claim 14, wherein a dose of 150 mg to 200 mg of sulindac is administered.

### Claim 20 (depends on 14)

The method of claim 14, wherein a dose of sulindac is administered once per day.

### Claim 21 (depends on 14)

The method of claim 14, wherein a dose of 300 mg to 400 mg of sulindac is administered once per day.

### Claim 22 (depends on 14)

The method of claim 14, wherein a dose of sulindac is administered twice per day.

### Claim 23 (depends on 14)

The method of claim 14, wherein a dose of 150 mg to 200 mg of sulindac is administered twice per day.

### Claim 24 (depends on 14)

The method of claim 14, wherein sulindac is administered orally.

### Claim 25 (depends on 14)

The method of claim 14, wherein sulindac is administered parenterally, transdermally, sublingually, rectally, or by inhalation.

### Claim 26 (depends on 14)

The method of claim 14, wherein the subject exhibits signs of hyperactivity, social anxiety, memory loss, or disruptive behaviour.

### Claim 27 (depends on 14)

The method of claim 14, wherein the subject exhibits signs of hyperactivity, memory loss, or disruptive behaviour.

### Claim 28 (depends on 14)

The method of claim 14, wherein the subject is human; and a dose of 300 mg to 400 mg of sulindac is administered once per day.

### Claim 29 (depends on 14)

The method of claim 14, wherein the subject is human; and a dose of 150 mg to 200 mg of sulindac is administered twice per day.

### Claim 30 (depends on 14)

The method of claim 14, wherein the subject is human; and a dose of 300 mg to 400 mg of sulindac is administered orally once per day.

### Claim 31 (depends on 14)

The method of claim 14, wherein the subject is human; and a dose of 150 mg to 200 mg of sulindac is administered orally twice per day.
